1. In Vivo
  2. >>Global Vision

Life Technologies Extends Thermo Fisher’s Reach Into Clinical Practice

Thermo Fisher’s $13.6 billion bid for Life Technologies is a blockbuster move within the instrumentation and consumables space, and also has implications for clinical practice. It’s another sign of the growing recognition that integrating clinical workflow is an important potential area for innovation and growth, along with the desire to move genomics tools into clinical use and the development of test content by nontraditional players in diagnostics.

Clearly a blockbuster consolidating move within the instrumentation and consumables space, the April acquisition of Life Technologies Corp. by Thermo Fisher Scientific Inc. is also a sign of the growing recognition that integrating clinical workflow is an important potential area for innovation and growth. As well, it reflects the desire to move genomics tools into clinical use and the interest among nontraditional players in pursuing diagnostics.

Thermo Fisher won a four-month bidding war for LifeTech, agreeing to shell out $13 billion in cash plus assumption of...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Global Vision

More from In Vivo

‘A Small Medtech Industry Ecosystem With An Outsized Global Influence’

 
• By Ashley Yeo

Entrepreneurialism is in the blood of Israel’s medtech innovators, but in a changing medtech world, the local ecosystem must address funding gaps and manufacturing and infrastructure needs. So says Ruti Alon, experienced Israeli medtech leader, investor and co-chair of the Biomed Israel conference.

Dealmaking Quarterly Statistics, Q2 2025

 
• By Maureen Riordan and Deanna Kamienski

During Q2, biopharma merger and acquisition deal value reached $24.6bn and drew in $60.7bn in potential deal value from alliances. Device company M&A values reached $223m, while in vitro diagnostics and research tools players’ M&A activity totaled $802m.

PBMs Tighten The Reins: Value Becomes The New Access Gatekeeper

 
• By Andrew Cox

Facing rising costs and tighter regulations, PBMs and insurers are accelerating the shift to value-based drug coverage, demanding stronger proof of therapeutic and economic benefit from pharma.